Multicenter, double blind, prospective study assessing ability of molecular panel as a predictive determinant for panitunumab plus FOLFOX (oxaliplatin, 5-fluorouracil and leucovorin) therapy in treating patients with K-ras and n-ras wild type metastatic colorectal cancer.

Trial Profile

Multicenter, double blind, prospective study assessing ability of molecular panel as a predictive determinant for panitunumab plus FOLFOX (oxaliplatin, 5-fluorouracil and leucovorin) therapy in treating patients with K-ras and n-ras wild type metastatic colorectal cancer.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Dec 2016

At a glance

  • Drugs Panitumumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms SUPER-PEAK
  • Most Recent Events

    • 07 Dec 2016 New trial record
    • 11 Oct 2016 Trial design presented at 41st European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top